OpenExamsFREE PRACTICE — ANY EXAM

Free ACVP Phase II Clinical Pathology Examination Practice Questions

250 free questions · Answer explanations · No signup required

View examination details, outline and sources

Loading selected examination banks…

Sample Practice Questions

Try these 10 sample questions from the ACVP Phase II Clinical Pathology Examination practice bank. Each includes the answer and explanation. Continue with the interactive practice above to review the full question set.

  1. 1A clinical pathologist examines the thin white buffy coat from centrifuged EDTA-anticoagulated blood of a healthy adult dog. Which cellular combination normally constitutes this layer?

    1. A. Mature erythrocytes and reticulocytes
    2. B. Nucleated leukocytes and platelets
    3. C. Nucleated erythrocytes and reticulocytes
    4. D. Mature erythrocytes and platelets

    Answer: B

    Explanation: The text describes the buffy coat as containing "nucleated cells (predominantly leukocytes) and platelets". This identifies the expected leukocyte–platelet composition of the white layer. The erythrocyte-rich layer lies below it; prominent nucleated erythrocytes can discolor a buffy coat but do not describe its normal composition in this adult dog.

    Reference: Veterinary Hematology, Clinical Chemistry, and Cytology, Third Edition — Laboratory Technology for Veterinary Medicine — Chapter 1, p. 4, Packed cell volume

  2. 2An impedance-based hematology analyzer counts canine cells passing through an aperture in a conductive electrolyte. Which cellular property is represented by the magnitude of an individual current deflection?

    1. A. Cellular granularity
    2. B. Hemoglobin concentration
    3. C. Nucleic-acid content
    4. D. Cellular volume

    Answer: D

    Explanation: CDC states, "The height of the electrical pulse is proportional to the cell volume." Thus pulse magnitude reflects volume in the stated impedance method. Granularity, hemoglobin concentration and nucleic-acid content require different measurements; none is the quantity represented by this pulse-height principle.

    Reference: CDC Laboratory Procedure Manual: Complete Blood Count with 5-Part Differential — Purpose and Principle of Test, CBC Analysis, printed page 3

  3. 3When evaluating a clinically healthy retired racing Greyhound, a pathologist considers documented breed differences rather than assuming that serum creatinine alone determines filtration. Which combination has been reported in healthy Greyhounds compared with non-Greyhound dogs?

    1. A. Higher creatinine concentration with lower GFR
    2. B. Lower creatinine concentration with higher GFR
    3. C. Higher creatinine concentration with higher GFR
    4. D. Lower creatinine concentration with lower GFR

    Answer: C

    Explanation: The review reports higher creatinine despite a "higher GFR" in studied Greyhounds. Increased muscle mass and creatinine production provide a plausible explanation. This documented combination prevents an automatic inference that every modest breed-associated creatinine increase signifies reduced filtration; it does not establish that every Greyhound is free of kidney disease.

    Reference: Clinical Pathology of Greyhounds and Other Sighthounds — Clinical Biochemistry, Urea nitrogen and creatinine, first paragraph

  4. 4A veterinary chemistry analyzer determines an electrolyte concentration using a selective membrane, an internal ion solution, and a reference electrode. Which primary signal does this ion-selective electrode system measure?

    1. A. Electrical charge transferred during the measurement
    2. B. Electrical potential across the membrane
    3. C. Electrical conductance across the membrane
    4. D. Electrical capacitance across the membrane

    Answer: B

    Explanation: The CDC method describes an ISE developing "an electrical potential (electromotive force, EMF)" from the selective membrane and ion-concentration difference. The reference electrode and circuits measure this voltage to derive concentration. Charge, conductance and capacitance are real electrical properties, but they are not the primary measured signal in the described potentiometric method.

    Reference: CDC NHANES Laboratory Procedure Manual — Sodium — Section 1, Summary of Test Principle and Clinical Relevance, ISE explanation, p. 3 of 22

  5. 5A pathologist evaluates the normal hormonal response to expansion of extracellular fluid volume in a dog. Which atrial hormone promotes sodium excretion and suppresses renin production?

    1. A. Angiotensin II
    2. B. Atrial natriuretic peptide
    3. C. Aldosterone
    4. D. Arginine vasopressin

    Answer: B

    Explanation: The study states, "ANP results in natriuresis and vasorelaxation and suppresses juxtaglomerular apparatus production of renin." Volume expansion stimulates this atrial hormone. Angiotensin II and aldosterone promote sodium retention, while vasopressin primarily regulates water conservation.

    Reference: The Renin–Angiotensin–Aldosterone System in Greyhounds and Non-Greyhound Dogs — Introduction, paragraph beginning Atrial natriuretic peptide (ANP) production

  6. 6While evaluating normal lymph-node histology from a laboratory rat, a pathologist identifies mature plasma cells and their precursors. In which compartment are these cells normally concentrated?

    1. A. The cortical lymphoid follicles
    2. B. The subcapsular lymphatic sinus
    3. C. The medullary cords
    4. D. The paracortical T-cell region

    Answer: C

    Explanation: NTP describes plasma cells and their precursors as "normally present in the medullary cords". The medullary cords are therefore the expected plasma-cell compartment. The cortical follicles, paracortex, and subcapsular sinus are distinct nodal compartments, not the normal site specified for this population.

    Reference: NTP Nonneoplastic Lesion Atlas — Lymph Node: Hyperplasia, Plasma Cell — Narrative, Comment, normal plasma-cell distribution sentence

  7. 7A laser-based hematology instrument examines cells moving through a flow cell. What does forward-angle light scatter principally indicate in the basic optical measurement described for cell sizing?

    1. A. Cellular hemoglobin concentration
    2. B. Cellular nucleic-acid concentration
    3. C. Cellular size
    4. D. Cellular antigen expression

    Answer: C

    Explanation: The textbook explains that "forward-angle scatter, is proportional to the size of the cell." In the basic optical sizing principle described, forward scatter therefore reflects cellular size. Hemoglobin concentration, nucleic-acid content and antigen expression involve other optical, dye-based or antibody-based measurements.

    Reference: Veterinary Hematology, Clinical Chemistry, and Cytology, Third Edition — Chapter 1, p. 10, Cell-counting and sizing technologies, light-scatter paragraph

  8. 8A clinically well retired racing Greyhound has a low basal total T4 compared with a general canine reference interval. Thyroid scintigraphy shows uptake within euthyroid reference limits. Which interpretation best accounts for these results?

    1. A. Breed-associated low basal thyroid hormone concentrations
    2. B. Primary thyroid failure with compensatory gland stimulation
    3. C. Autonomous thyroid secretion with suppressed pituitary stimulation
    4. D. Thyroid hormone excess caused by increased circulating binding protein

    Answer: A

    Explanation: The review documents thyroid uptake within limits for "euthyroid dogs" despite low basal thyroid hormones in evaluated Greyhounds. This supports a breed-associated result rather than diagnosing hypothyroidism from total T4 alone. Primary gland failure, autonomous hormone excess, and binding-protein-associated hormone excess do not explain this specific combination. Clinical and additional endocrine findings remain relevant if disease is suspected.

    Reference: Clinical Pathology of Greyhounds and Other Sighthounds — Clinical Biochemistry, Thyroid hormones, first paragraph

  9. 9A species-validated hormone assay captures the analyte with an immobilized antibody and binds a second, enzyme-labeled antibody to the captured analyte. After washing, substrate conversion provides the measured signal. Which assay format does this architecture represent?

    1. A. Competitive radioimmunoassay
    2. B. Immunoturbidimetric assay
    3. C. Two-site immunoenzymometric assay
    4. D. Indirect immunofluorescence assay

    Answer: C

    Explanation: CDC describes this capture-and-enzyme-labeled-antibody architecture as a "two-site immunoenzymometric assay". Two antibodies bind the analyte to generate the measured enzyme-associated signal. The alternative formats are genuine immunologic methods, but competition with radiolabel, turbidity from immune complexes, and indirect fluorescent labeling do not match the specified architecture.

    Reference: CDC NHANES 2013–2014 — Insulin Laboratory Data Documentation — Description of Laboratory Methodology, first paragraph

  10. 10When interpreting renin–angiotensin–aldosterone physiology in a dog, a pathologist traces the conversion of circulating angiotensin I to angiotensin II. Which enzyme catalyzes this conversion?

    1. A. Renin
    2. B. Aldosterone synthase
    3. C. Angiotensin-converting enzyme
    4. D. 11β-hydroxylase

    Answer: C

    Explanation: The study identifies ACE as the enzyme that "cleaves circulating angiotensin I to form angiotensin II." Renin acts earlier on angiotensinogen. Aldosterone synthase and 11β-hydroxylase participate in adrenal steroid synthesis rather than this circulating peptide conversion.

    Reference: The Renin–Angiotensin–Aldosterone System in Greyhounds and Non-Greyhound Dogs — Discussion, paragraph beginning ACE activity was used as a proxy for angiotensin II

Topics in this practice bank

These topics describe the available practice for ACVP Phase II Clinical Pathology Examination. Review the examination outline and its sources for scope and allocation details.

  • Task 1: Identify and interpret microscopic features of blood, bone marrow, fluids (including urine), and tissues (i.e. cytology and histology) from domestic and non-domestic animals. (published approximate allocation: ~33%)
    • Knowledge: Normal tissue or fluid components, including species variations (e.g. leukocyte proportions, bone marrow lineages, elements in body cavity fluids and tissue aspirates, histopathology architecture for commonly aspirated tissue such as liver and lymph nodes)
    • Knowledge: Normal cell morphology, including species and stain variations (e.g. rapid stain versus Wright-Giemsa, canine versus feline RBCs, heterophils versus eosinophils in avian and reptilian blood smears)
    • Knowledge: Artifactual and non-pathologic findings (e.g. stain precipitate, formalin artifact, urinalysis contaminants, cell changes in aged blood samples)
    • Knowledge: Infectious organism morphology, and those most likely to occur in a particular cell or tissue (e.g. rickettsial morulae in neutrophils, Pythium spp. in gastrointestinal aspirate, blastomycosis in cutaneous biopsy)
    • Knowledge: Most likely causes of inflammatory patterns in particular tissues (e.g. eosinophilic pleocytosis in CSF, pyogranulomatous dermatitis, neutrophilic arthritis, lymphocytosis on blood smears)
    • Knowledge: Neoplastic cell and tissue morphology (e.g. features of malignancy, architecture patterns)
    • Knowledge: Most likely diagnosis(es) associated with specific morphologic abnormalities (e.g. Melamed-Wolinska bodies and urothelial carcinoma, calcareous corpuscles and trematode infections)
    • Knowledge: Most likely diagnosis(es) associated with cytochemical, histochemical, and immunostain results (e.g. Mycobacterium and acid fast, osteosarcoma and ALP staining, CD3 and CD79a and lymphoma, reticulin and trichrome in bone marrow)
    • Skill: Identifying abnormal microscopic features in images (e.g. etiologic agents, cellular inclusions, blood cell morphology, criteria of malignancy)
    • Skill: Identifying multiple disease processes and the likely primary versus secondary process (e.g. fluid with lymphoma and secondary septic inflammation from gastrointestinal rupture)
    • Skill: Differentiating artifactual changes from non-pathologic and pathologic abnormalities (e.g. Pelger-Huet abnormality (needs to be anomaly, not abnormality) versus true inflammatory leukogram, lysosomal storage disease inclusions versus Doehle bodies, stain precipitate versus hemoparasite)
    • Skill: Differentiating inflammatory from hyperplastic/reactive from neoplastic conditions (e.g. myeloid hyperplasia with left shift in bone marrow versus acute leukemia, reactive mesothelial cells from carcinoma in peritoneal fluid)
    • Skill: Formulating a diagnosis using image findings and clinical information
  • Task 2: Interpret static visual test results of healthy and diseased domestic and non-domestic animals. (published approximate allocation: ~15%)
    • Knowledge: Routine and advanced hematology instrumentation methodology (e.g. Advia, Sysmex, TEG, point-of-care devices)
    • Knowledge: Routine and advanced hematology data
    • Knowledge: Macroscopic hematology test methodology (e.g. cross match, blood typing)
    • Knowledge: Microscopic hematology test methodology (e.g. cross-match, Coomb’s test, saline dispersion)
    • Knowledge: Marker selection for liquid and solid tissue sample immunophenotyping (e.g. CD3 for T cell, cytokeratin for epithelial)
    • Knowledge: Cytochemical and histochemical stains (e.g. Congo red for amyloid, alcian blue for mucin, GMS)
    • Knowledge: How sample attributes (i.e. gross appearance) impact test results
    • Knowledge: Standard QA/QC data acquisition, presentation, validation, and relevance (e.g. Levy-Jennings, Bland-Altman plots)
    • Knowledge: Clonality test plots (e.g. electrophoresis, PCR)
    • Knowledge: Relevant visual tests included within the recent veterinary literature
    • Skill: Interpreting routine hematology cytograms
    • Skill: Interpreting advanced microscopic and macroscopic hematology test results
    • Skill: Interpreting platelet and hemostasis testing results
    • Skill: Interpreting flow cytometry plots
    • Skill: Interpreting cytochemical, histochemical, and immunochemical stains
    • Skill: Interpreting quality assurance and quality control graphical data
    • Skill: Interpreting protein electrophoretograms and immunofixation reactions
    • Skill: Interpreting PCR clonality traces
  • Task 3: Evaluate and interpret clinicopathologic data of healthy and diseased domestic and non-domestic animals. (published approximate allocation: ~25%)
    • Knowledge: Expected physiology for species, breed, age, and sex and reproductive differences
    • Knowledge: Pathophysiology in organ systems (e.g. kidney, liver) and associated biomarkers (e.g. urea nitrogen, creatinine, bilirubin)
    • Knowledge: Pathophysiology in systemic processes (e.g. acid-base, lipid metabolism, proteins) and associated biomarkers (e.g. pH, HCO3, triglycerides, CRP, SAA)
    • Knowledge: Enzymology (e.g. isoenzymes, half-lives, tissue specificity, species differences)
    • Knowledge: Ancillary (e.g. disease specific or advanced) tests to confirm diagnosis (e.g. endocrine disease)
    • Knowledge: Biologic variability in standard laboratory animals including use of control and pretreatment data
    • Knowledge: Current language pertaining to clinicopathologic data and diagnoses (e.g. normal versus healthy, range versus interval, specific current clinicopathologic terms)
    • Skill: Interpretation of individual and population-based laboratory data
    • Skill: Integrating laboratory abnormalities into a diagnosis or a refined list of differentials
    • Skill: Selection and interpretation of appropriate ancillary tests
  • Task 4: Understand the principles of commonly used laboratory instrumentation and methods. (published approximate allocation: ~10%)
    • Knowledge: Analyzer and test procedure methodologies (e.g. flow versus impedance, direct versus indirect measurements)
    • Knowledge: Sample types and collection methods, errors and interferences on test results (e.g. pre-analytical, analytical, post-analytical)
    • Knowledge: Procedures for reference interval determination and validation (e.g. index of individuality, sample size)
    • Knowledge: The principles of microscopy (e.g. parts of microscope, fundamentals of digital scanning)
    • Knowledge: Quality control and quality assurance including relevant statistics (e.g. six sigma, total allowable error)
    • Knowledge: Test properties and selection (e.g. sensitivity, specificity, predictive values, ROC)
    • Knowledge: Procedures for method validation (e.g. imprecision, species specificity, bias determination)
    • Knowledge: Procedures for and uses of routine, cytochemical, histochemical, and immunochemical stains (e.g. New methylene blue, ALP, Wright- Giemsa)
    • Skill: Identifying erroneous test results and the associated cause
  • Task 5: Apply the pathophysiology of disease in domestic and non-domestic animals to manifestations in clinicopathologic test results. (published approximate allocation: ~17%)
    • Knowledge: Normal physiologic mechanisms (e.g. renal handling of water, electrolytes, and waste products; hepatic uptake, conjugation, and excretion of metabolites; thyroid and adrenal hormone production)
    • Knowledge: Neoplastic disease pathogenesis (e.g. paraneoplastic hypercalcemia, acute tumor lysis syndrome)
    • Knowledge: Metabolic disease pathogenesis (e.g. corticosteroid leukograms and hyperglycemia, diabetic ketoacidosis, negative energy balance and hepatic lipidosis)
    • Knowledge: Infectious disease pathogenesis (e.g. babesiosis and anemia, fungal infections and hypercalcemia)
    • Knowledge: Inflammatory disease pathogenesis (e.g. immune mediated polyarthritis, pancreatitis)
    • Knowledge: Pathogenesis of toxicity (e.g. Heinz bodies/eccentrocytes and oxidative injury)
    • Knowledge: Hemodynamic disease pathogenesis (e.g. effusion formation, congenital and acquired hemostatic deficiencies, disseminated intravascular coagulation)
    • Knowledge: Degenerative disease pathogenesis (e.g. hepatic insufficiency and biochemical changes, renal disease and biomarkers)
    • Knowledge: Genetic disease pathogenesis (e.g. RBC enzymopathies, leukocyte adhesion deficiency)
    • Knowledge: Species variations in physiology and pathogenesis (e.g. hepatocellular and cholestatic liver enzymes, major acute phase proteins, likely causes of oxidative injury)
    • Skill: Integrating mechanisms of disease with clinicopathologic test results

How to use these free practice questions

Choose an answer, check the explanation, and review your progress by chapter. Practice questions and explanations are free to access without signing up.

These are independent study questions, not actual examination items. For examination requirements and official information, view ACVP Phase II Clinical Pathology Examination details.